XTX Topco Ltd Buys Shares of 12,998 Grail, Inc. (NASDAQ:GRAL)

XTX Topco Ltd bought a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,998 shares of the company's stock, valued at approximately $232,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Mariner LLC bought a new stake in shares of Grail during the fourth quarter worth about $190,000. Barclays PLC bought a new stake in shares of Grail during the fourth quarter worth about $429,000. Reynders McVeigh Capital Management LLC bought a new stake in Grail in the 4th quarter worth about $1,784,000. Carson Advisory Inc. bought a new stake in Grail in the 4th quarter worth about $246,000. Finally, Rockefeller Capital Management L.P. bought a new stake in Grail in the 4th quarter worth about $2,490,000.

Grail Stock Down 0.2 %

NASDAQ:GRAL traded down $0.09 during midday trading on Tuesday, hitting $36.81. The company had a trading volume of 1,515,161 shares, compared to its average volume of 1,224,964. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $63.99. The stock's fifty day moving average price is $30.83 and its 200-day moving average price is $24.58.

Grail (NASDAQ:GRAL - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to analysts' expectations of $35.33 million. As a group, research analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GRAL. Canaccord Genuity Group began coverage on shares of Grail in a research report on Monday, April 21st. They issued a "buy" rating and a $32.00 price objective for the company. Morgan Stanley upped their price objective on shares of Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 18th.

Insider Buying and Selling at Grail

In other Grail news, President Joshua J. Ofman sold 2,109 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.20, for a total transaction of $65,800.80. Following the completion of the transaction, the president now owns 559,673 shares of the company's stock, valued at $17,461,797.60. This represents a 0.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the transaction, the chief executive officer now directly owns 828,662 shares of the company's stock, valued at $25,862,541.02. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,550 shares of company stock valued at $360,436 in the last 90 days.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.